Literature DB >> 20439344

Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients.

Z Sun1, J Chen2, J Aakre1, R S Marks3, Y Y Garces4, R Jiang1, O Idowu5, J M Cunningham6, Y Liu7, V S Pankratz1, P Yang8.   

Abstract

BACKGROUND: Small-cell lung cancer (SCLC) carries the worst prognosis among lung cancer diagnoses. Combined radiation and chemotherapy is the standard of care; however, treatment outcomes vary. Variability in the rate at which chemotherapy agents are metabolized and in the capacity of repairing DNA damage has been hypothesized to be partly responsible for the treatment response variation. Genes in the glutathione metabolism and DNA repair pathways were tested through tag single-nucleotide polymorphisms (SNPs) to assess their association with survival in SCLC. PATIENTS AND METHODS: Blood DNA from 248 patients with primary SCLC was genotyped for 419 tag SNPs from 49 genes in the glutathione and DNA repair pathways. Association analyses with patient survival were carried out at single-SNP, whole-gene, and haplotype levels after adjusting for age, gender, tumor stage, treatment modalities, and smoking history.
RESULTS: Among the 375 SNPs successfully genotyped, 21 SNPs, located on 11 genes, showed significant association with survival. Whole-gene analyses confirmed 3 of the 11 genes: GSS, ABCC2, and XRCC1. Haplotype analyses of these three genes identified haplotype combinations and genomic locations underlying the observed SNP associations.
CONCLUSION: Genetic variations in genes involved in the glutathione and DNA repair pathways are associated with SCLC survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20439344      PMCID: PMC2946864          DOI: 10.1093/annonc/mdq212

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  29 in total

1.  Score tests for association between traits and haplotypes when linkage phase is ambiguous.

Authors:  Daniel J Schaid; Charles M Rowland; David E Tines; Robert M Jacobson; Gregory A Poland
Journal:  Am J Hum Genet       Date:  2001-12-27       Impact factor: 11.025

2.  Survival after treatment of small-cell lung cancer: an endless uphill battle.

Authors:  B S Glisson; W K Hong
Journal:  J Natl Cancer Inst       Date:  1997-12-03       Impact factor: 13.506

3.  The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy.

Authors:  Sang Min Yoon; Yun-Chul Hong; Heon Joo Park; Jong-Eun Lee; Sang Yoon Kim; Jong Hoon Kim; Sang-Wook Lee; So-Yeon Park; Jung Shin Lee; Eun Kyung Choi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-11-01       Impact factor: 7.038

Review 4.  Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review.

Authors:  Ping Yang; Jon O Ebbert; Zhifu Sun; Richard M Weinshilboum
Journal:  J Clin Oncol       Date:  2006-04-10       Impact factor: 44.544

5.  Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases.

Authors:  Zhifu Sun; Marie-Christine Aubry; Claude Deschamps; Randolph S Marks; Scott H Okuno; Brent A Williams; Hiroshi Sugimura; V Shane Pankratz; Ping Yang
Journal:  J Thorac Cardiovasc Surg       Date:  2006-05       Impact factor: 5.209

6.  Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis.

Authors:  Dianke Yu; Xuemei Zhang; Ju Liu; Peng Yuan; Wen Tan; Yongli Guo; Tong Sun; Dan Zhao; Ming Yang; Junniao Liu; Binghe Xu; Dongxin Lin
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

7.  Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.

Authors:  Kazuma Kiyotani; Taisei Mushiroda; Michiaki Kubo; Hitoshi Zembutsu; Yuichi Sugiyama; Yusuke Nakamura
Journal:  Cancer Sci       Date:  2008-02-19       Impact factor: 6.716

Review 8.  Targeted therapy in combination with gemcitabine in non-small cell lung cancer.

Authors:  Rafael Rosell; Lucio Crino; Kathleen Danenberg; Giorgio Scagliotti; Gerold Bepler; Miquel Taron; Vicente Alberola; Mariano Provencio; Carlos Camps; Filippo De Marinis; Jose Javier Sanchez; Ramon Peñas
Journal:  Semin Oncol       Date:  2003-08       Impact factor: 4.929

9.  Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients.

Authors:  Jun Chen; Ruoxiang Jiang; Yolanda I Garces; Aminah Jatoi; Shawn M Stoddard; Zhifu Sun; Randolph S Marks; Yunpeng Liu; Ping Yang
Journal:  Lung Cancer       Date:  2009-06-03       Impact factor: 5.705

10.  Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

Authors:  Wei Zhou; Sarada Gurubhagavatula; Geoffrey Liu; Sohee Park; Donna S Neuberg; John C Wain; Thomas J Lynch; Li Su; David C Christiani
Journal:  Clin Cancer Res       Date:  2004-08-01       Impact factor: 12.531

View more
  18 in total

1.  Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.

Authors:  Yafei Li; Zhifu Sun; Julie M Cunningham; Marie C Aubry; Jason A Wampfler; Gary A Croghan; Cassandra Johnson; Danli Wu; Jeremiah A Aakre; Julian Molina; Liewei Wang; V Shane Pankratz; Ping Yang
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guerin Instillation for Non-muscle Invasive Bladder Cancer.

Authors:  Hung-Lung Ke; Jie Lin; Yuanqing Ye; Wen-Jeng Wu; Hui-Hui Lin; Hua Wei; Maosheng Huang; David W Chang; Colin P Dinney; Xifeng Wu
Journal:  Ann Surg Oncol       Date:  2015-04-08       Impact factor: 5.344

3.  Genetic variations and patient-reported quality of life among patients with lung cancer.

Authors:  Jeff A Sloan; Mariza de Andrade; Paul Decker; Jason Wampfler; Curtis Oswold; Matthew Clark; Ping Yang
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

4.  Systematic evaluation of genetic variants in three biological pathways on patient survival in low-stage non-small cell lung cancer.

Authors:  V Shane Pankratz; Zhifu Sun; Jeremiah Aakre; Yan Li; Cassandra Johnson; Yolanda I Garces; Marie C Aubry; Julian R Molina; Dennis A Wigle; Ping Yang
Journal:  J Thorac Oncol       Date:  2011-09       Impact factor: 15.609

5.  Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy.

Authors:  Barry S Rosenstein
Journal:  Pharmacogenomics       Date:  2011-02       Impact factor: 2.533

6.  Associations Between Genetic Polymorphisms Within Transporter Genes and Clinical Response to Methotrexate in Chinese Rheumatoid Arthritis Patients: A Pilot Study.

Authors:  Han Cen; Qin-Wen Wen; Han-Qing Zhang; Hang Yu; Zhen Zeng; Ting Jin; Ting-Hui Wang; Wen Qin; Hua Huang; Xiu-Di Wu
Journal:  Pharmgenomics Pers Med       Date:  2022-04-12

Review 7.  Review of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments.

Authors:  Rao Khalid Mehmood
Journal:  Oncol Rev       Date:  2014-09-23

8.  Associations of LIG4 and HSPB1 genetic polymorphisms with risk of radiation-induced lung injury in lung cancer patients treated with radiotherapy.

Authors:  Feng Xu; Ji-Chang Han; Ya-Jun Zhang; Yi-Jie Zhang; Xiao-Chun Liu; Guan-Bin Qi; Dan Liu; Yan-Zhi Chen; Yu-Xia Zhao; Lu Bai
Journal:  Biomed Res Int       Date:  2015-02-25       Impact factor: 3.411

9.  Evaluation of copy number variation and gene expression in neurofibromatosis type-1-associated malignant peripheral nerve sheath tumours.

Authors:  Laura E Thomas; Jincy Winston; Ellie Rad; Matthew Mort; Kayleigh M Dodd; Andrew R Tee; Fionnuala McDyer; Stephen Moore; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2015-02-15       Impact factor: 4.639

10.  Current Understanding of Membrane Transporters as Regulators or Targets for Cisplatin-Induced Hearing Loss.

Authors:  Kyle Z Pasquariello; Jason M Dey; Jason A Sprowl
Journal:  Mol Pharmacol       Date:  2021-07-30       Impact factor: 4.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.